Levi & Korsinsky, LLP announces that a SAVA class action lawsuit has been filed on behalf of investors who purchased Cassava Sciences, Inc.(SAVA) securities between February 2, 2021, and August 24, 2021 For more on the SAVA Lawsuit please contact us today.

According to the Cassava lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:  (a) the quality and integrity of the scientific data supporting Cassava’s claims for simufilam’s, a small molecule drug designed to treat Alzheimer’s disease, efficacy had been overstated; (b) the scientific data supporting Cassava’s claims for simufilam’s efficacy were biased; and (c) as a result of the foregoing, Defendants’ positive statements during the Class Period about the Company’s business metrics and financial prospects and the likelihood of Food and Drug Administration approval was false and misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE SAVA CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Cassava you have until October 26, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com